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Abstract
Between February and May 2020, during the first wave of the COVID-19 pandemic, paediatric emergency departments in 12
European countries were prospectively surveyed on their implementation of SARS-CoV-2 disease (COVID-19) testing and infection
control strategies. All participating departments (23) implemented standardised case definitions, testing guidelines, early triage and
infection control strategies early in the outbreak. Patient testing criteria initially focused on suspect cases and later began to include
screening, mainly for hospital admissions. Long turnaround times for test results likely put additional strain on healthcare resources.
Conclusion: Shortening turnaround times for SARS-CoV-2 tests should be a priority. Specific paediatric testing criteria are needed.
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What is Known:
• WHO and public health authorities issued case definitions, testing and infection control recommendations for COVID-19 in January.
• SARS-CoV-2 testing was made available across Europe in February.
What is New:
• Paediatric emergency departments implemented COVID-19-specific procedures rapidly, including case definitions, testing guidelines and early triage.
• A third of surveyed departments waited more than 24 h for SARS-CoV-2 test to be reported, resulting in additional strain on resources.
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Abbreviations
A&E Accident and emergency department
ARI Acute respiratory infection
ECDC European Centre for Disease
Prevention and Control
HSCT Haematopoietic stem cell transplantation
LRTI Lower respiratory tract infection
PICU Paediatric intensive care unit
SARS-CoV-2 Severe acute respiratory syndrome
coronavirus 2
UK United Kingdom
WHO World Health Organization
Background
European reference laboratories established widespread ca-
pacities for testing for severe acute respiratory syndrome co-
ronavirus 2 (SARS-CoV-2) within a matter of days after a
diagnostic test was made publicly available [1, 2]. World
Health Organization (WHO) and public health authorities in
Europe issued case definitions, testing and infection control
recommendations for COVID-19 in January 2020.
The current understanding of COVID-19 in paediatric pa-
tients is that children more often have mild disease compared
to adults [3, 4]. Current knowledge suggests that the peak of
infectiousness of SARS-CoV-2 infection occurs a few days
before and after the onset of symptoms, meaning that pre-
symptomatic people are able to transmit the infection [5].
Transmission unobserved by public health authorities occurs
frequently, with at least one-third of cases having been unde-
tected during the early epidemic [6, 7].
The aim of this study was to describe the implementation of
testing and infection control strategies and their evolution in
paediatric emergency departments in Europe.
Methods
From mid-February to the first week of May 2020, we sur-
veyed all European paediatric collaboration sites within the
PENTA ID paediatric research network weekly for develop-
ments in their testing and infection control strategies. Portable
document format (pdf) survey forms were sent out by email to
contact officers at 78 paediatric departments across Europe.
The survey form is available as an online supplement to this
article. Completed and signed survey forms were handed in by
return email. Missing weekly replies were imputed as last
observation carried forward.
Results
Paediatric departments of 23 mostly tertiary care hospitals in
12 European countries (Belgium, Germany, France, Italy,
Poland, Portugal, the UK, the Netherlands, Greece, Spain,
Lithuania and Switzerland) participated in the surveys (re-
sponse rate 29%). Multiple sites participated in the UK (5, 3
tertiary and 2 secondary level), Germany (5, 4 tertiary and 1
secondary level), Spain (3, 1 network of sites representing the
Madrid region, 1 tertiary and 1 secondary level) and Poland
(2, both tertiary level). In each of the remaining countries
(Belgium, France, Italy, Portugal, the Netherlands, Greece,
Lithuania and Switzerland), one site participated.
Rapid implementation and evolution of standardised
case definitions
By the end of February 2020, all hospitals had implemented
standardised case definitions for suspected COVID-19 cases, with
the majority (16 out of 21 participating at that point in time, 76%)
following national government or public health authority guide-
lines and three directly following WHO guidelines. Standardised
definitions of suspected cases showed high similarity between
sites. All definitions consisted of a clinical component of acute
respiratory infection and an epidemiological component of possi-
ble exposure to the virus. The latter changed between February
and April: initially, definitions at all sites required contact within
14 days with a confirmed case or travel to specified geographic
areas; in time, this changed to staying in any area with ongoing
community transmission. Twenty participating sites used
suspected case definitions from the beginning that did not exclude
patients on detection of an alternative pathogen. Two of the
Spanish sites and one site in Poland initially excluded patientswith
confirmed alternative diagnoses of respiratory infections from be-
ing suspect cases for COVID-19. This changed by April
at all three sites, so that afterwards detection of another
pathogen that could explain the respiratory symptoms
no longer excluded a patient from being a suspect case
and from undergoing SARS-CoV-2 testing.
Strict testing guidelines in line with case definitions
Ten sites (43%) reported that they strictly only tested patients for
SARS-CoV-2 if they matched the definition of a suspected case.
Another 12 (52%) had a policy to only test patients matching the
case definition but reported that exceptions occurred regularly.
Until April, no site reported that their decision to test patients was
based on separate local guidelines. In April, several German and
UK sites started broader testing, first with testing of patients
admitted to oncology or intensive care units and from the end
of April with routine screening of all admitted patients. Table 1
shows example developments of testing guidelines at four par-
ticipating children’s emergency departments.
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In terms of sampling site, 52% of the participating
hospitals restricted testing to upper respiratory samples,
while 48% obtained upper and lower respiratory sam-
ples if the latter could be obtained.
Although discharge and infection control strategies
after admission relied heavily on test results, by the
end of the survey period only 9 hospitals (39%) re-
ceived test results multiple times daily, while another
7 (30%) had waiting times of more than 24 h before
test results would be back. At all but two sites, where
faster turnaround times could be achieved, expected
time to test results did not change over the survey pe-
riod. By the beginning of March, 9 (43%) were
discharging patients with pending test results when they
were clinically stable. Three of the seven hospitals
where results took more than 24 h to come back would
not discharge patients while test results were pending,
regardless of whether the patients were clinically stable.
By mid-March all hospitals were discharging patients
with pending test results.
Until the beginning of March, sites saw up to 30 suspected
cases per week. While only one site (in Germany) had a child
positive for SARS-CoV-2, 67% of sites had already provided
care to suspected cases of SARS-CoV-2. At the different sites,
the highest number of patients tested per week differed widely
between 7 per week for a secondary care hospital in Western
Germany and 112 for a specialised tertiary care children’s
hospital in North England. Community test centres for
COVID-19 opened across Germany in early to mid-March
and in the UK only in April. Opening of community test
centres in proximity to the surveyed sites coincided with vary-
ing stages of development of overall case numbers in the
areas. Therefore, our data allow no firm conclusion on wheth-
er opening of community test centres alleviated patient pres-
sure on paediatric emergency departments.
Rapid implementation of infection control strategies
Most departments used early clinical triage at the emergency
department to separate suspected cases from other patients
from the beginning of the survey period. Only one site (in
Greece) initially did not triage but changed this in the last
week of February. Two UK hospitals had plans to refer pa-
tients with positive test results to other hospitals for admission,
and eight hospitals were planning to place multiple patients
tested positive in cohort isolation if limited capacity for indi-
vidual isolation occurred.
At most hospitals, staff used respirators, i.e. filtering face
piece (FFP) masks, when treating suspected cases in the emer-
gency department. In contrast, staff at four UK sites, in the
Netherlands and at one site in Poland used surgical masks
only. This did not change over the survey period.
Discussion
In the early stages of the COVID-19 pandemic, paediatric
emergency departments implemented standardised case defi-
nitions, testing guidelines and infection control measures rap-
idly. While this is an important and reassuring finding regard-
ing the preparedness of paediatric emergency care in Europe,
it may be a limitation of this survey that our sample of hospi-
tals was biased towards tertiary care hospitals with strong
international research links.
Although infection control strategies and even dis-
charge of patients relied heavily on receiving SARS-
CoV-2 test results, most hospitals only received these
after considerable delay, often more than 24 h.
Shortening turnaround times for tests should be a prior-
ity. Prior to discharge, infection control measures on
uninfected patients awaiting test results place a huge
burden on emergency care resources. Most departments
rightly responded by discharging patients while test re-
sults were pending. This does not, however, mitigate
against the public health impact of delayed result
reporting on efficient contact tracing and subsequent
isolation or quarantine of contacts in the community.
The guidelines for testing focused on two aims: establish-
ing aetiology in children with symptoms of ARI and exclud-
ing infection for inpatient infection control purposes. This was
a necessary restriction while numbers of new infections were
high and capacities for testing were limited. We believe that in
the current situation with vastly expanded laboratory capaci-
ties, a broader approach with more testing of mildly symptom-
atic patients or asymptomatic contacts may be warranted. To
allocate testing resources responsibly, we believe that specific
testing criteria for the paediatric population are needed be-
cause both the individual risk of children to suffer from severe
disease and to sustain transmission in the community differ
from that in adults [10, 11].
Children and adolescents suffer serious consequences from
school closures and allowing schools to re-open has positive
social, psychological and economic implications [12].
Benefits of broader access to testing may include the ability
to detect outbreaks in day care facilities and schools earlier in
order to limit spread of infections while maintaining as much
normality as possible for children and adolescents.
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